Everest Medicines Ltd.

As of June 30, 2026, Everest Medicines Ltd. carries a market capitalization of 969.49M, placing it among publicly traded companies globally. Its enterprise value stands at 963.56M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Everest Medicines Ltd.'s next confirmed earnings release is scheduled for April 1, 2027.

As of June 30, 2026, Everest Medicines Ltd. has 353.83M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Everest Medicines Ltd. maintains a current ratio of 3.77, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Everest Medicines Ltd.'s stock has declined approximately 31.43% over the past 52 weeks. The 50-day moving average sits at 3.41, while the 200-day moving average is 3.56.

As of June 30, 2026, Everest Medicines Ltd. holds 262.63M in cash and equivalents against 256.70M in total debt, resulting in a net debt position of 52.03M. Total book value stands at 674.64M, with working capital of 286.11M providing operational flexibility.